Applicability of the Lung-molGPA Index in Non-Small Cell Lung Cancer Patients with Different Gene Alterations and Brain Metastases

As one of the most common malignant tumors, lung cancer is a leading cause of cancer-related mortality in China and worldwide [1]. Non-small cell lung cancer (NSCLC) accounts for 85% of primary lung cancers [2], 25-40% of which develop brain metastases (BM) [3,4]. In the past, survival after the occurrence of BM was poor, and treatment was often considered futile [5,6]. With the recent advent of molecular targeted therapies, prolonged survival has been achieved in patients with BM and gene alterations [7 –10], benefiting from EGFR TKIs such as icotinib [11], erlotinib [12] and Osimertinib [13], as well as ALK TKIs such as alectinib [14] and lorlatinib [15].

Source: Lung Cancer - August 30, 2018 Category: Cancer & Oncology Authors: Author: Kaiyan Chen, Xiaoqing Yu, Fanrong Zhang, Yanjun Xu, Peng Zhang, Zhiyu Huang, Yun Fan Source Type: research